Probenecid, an FDA-approved gout treatment with “powerful antiviral properties” and minimal side effects, is “a prime candidate” for treating COVID-19 according to a new study.SciTechDaily reports on recent research from the University of Georgia, where they found that probenecid “works as a prophylactic prior to virus exposure and as a post-exposure treatment in animal models against SARS-CoV-2 and flu.”Ralph Tripp, lead author of the study, concluded, “This antiviral works for all RNA respiratory viruses we tested, including SARS-CoV-2. RSV, coronavirus and flu all circulate in the same season. Bottom line is you can potentially reduce infection and disease using this...